Page 1

inflaRx • • InflaRx Reports Third Quarter 2021 Financial & Operating Results Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa ( HS ) lesions for Phase III program with vilobelimab in HS In Phase Ila open - label study with vilobelimab in Pyoderma Gangraenosum , 6 out of 7 patients in highest dose cohort showed clinical remission and closure of target ulcer InflaRx awarded grant by German government of up to € 43.7 million to advance development of vilobelimab for treatment of severe COVID - 19 patients Enrollment completed in Phase III part of Phase II / III study evaluating vilobelimab in severe COVID - 19 ; Topline results expected in Q1 2022 Cash , cash equivalents and financial assets of approximately € 120.6 million as of September 30 , 2021 - Jena , Germany , November 5 , 2021 InflaRx ( Nasdaq : IFRX ) , a clinical - stage biopharmaceutical company developing anti - inflammatory therapeutics by targeting the complement system , announced today financial and operating results for the three and nine months ended September 30 , 2021 . " We are pleased by the recent developments with our immunodermatology franchise with vilobelimab , including the outcome of the Type A meeting with the FDA for Hidradenitis Suppurativa and positive results in our study in Pyoderma Gangraenosum , ” said Prof. Niels C. Riedemann , Chief Executive Officer and Founder of InflaRx . " Before year end , we expect additional important catalysts for the Company , including data from our Phase II AAV study . We also are grateful for the grant from the German government to assist in advancing our COVID - 19 program , from which topline data are expected in Q1 2022. " Recent Corporate Highlights and R & D Update Vilobelimab in Hidradenitis Suppurativa ( HS ) In September , InflaRx announced the outcome of its Type A meeting with the U.S. Food & Drug Administration ( FDA ) . The FDA response was supportive of a pivotal study program that focuses on patients with active draining tunnels and a new primary efficacy endpoint that will include measuring the reduction of all three lesions - inflammatory nodules , abscesses and